Cargando…

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?

INTRODUCTION: Myeloma multiplex is defined by the presence of monoclonal plasma cell population in the bone marrow>10%,M protein in the serum and/or urine ,and clinical evidence of end organ damage like hypercalcemia ,renal failure, anemia, or bone lesions. In the most hematologic malignancies th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Svetlana Balkanov, Krstevska, Sotirova, Tatjana, Genadieva, Stavrik Sonja, Cevreska, Lidija, Stojanovik, Aleksandar, Balkanov, Trajan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AVICENA, d.o.o., Sarajevo 2014
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4035132/ https://www.ncbi.nlm.nih.gov/pubmed/24944541 http://dx.doi.org/10.5455/msm.2014.26.134-136

Ejemplares similares

Tretatment Approach of Nontransplant Patients with Multiple Myeloma
por: Krstevska, Svetlana B., et al.
Publicado: (2014)

Osteonecrosis of the Jaw After Bisphosphonates Treatment in Patients with Multiple Myeloma
por: Krstevska, Svetlana, et al.
Publicado: (2015)

Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes
por: Sotirova, Tatjana, et al.
Publicado: (2014)

Hairy Cell Leukemia Treatment: Where We Are Now?
por: Krstevska, Svetlana, et al.
Publicado: (2011)

Determination of the Diagnostic Values of Asymmetric Dimethylarginine as an Indicator for Evaluation of the Endothelial Dysfunction in Patients with Rheumatoid Arthritis
por: Spasovski, Dejan, et al.
Publicado: (2013)

Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases
por: Darkovska-Serafimovska, Marija, et al.
Publicado: (2018)

Analysis of Factors that Influence Hematopoietic Recovery in Autologous Transplanted Patients with Hematopoietic Stem Cells from Peripheral Blood
por: Grubovic, Rada M., et al.
Publicado: (2017)

Determination of Acyclovir in Human Plasma Samples by HPLC Method with UV Detection: Application to Single-Dose Pharmacokinetic Study
por: Zendelovska, Dragica, et al.
Publicado: (2015)

Radiolabeled tirofiban – a potential radiopharmaceutical for detection of deep venous thrombosis
por: Darkovska-Serafimovska, Marija, et al.
Publicado: (2016)

Does Cannabis Extract Obtained From Cannabis Flowers With Maximum Allowed Residual Level of Aflatoxins and Ochratoxin a Have an Impact on Human Safety and Health?
por: Serafimovska, Tijana, et al.
Publicado: (2021)

A Case of Internal Carotid Artery Thrombosis associated with Thalidomide Administration in Multiple Myeloma
por: Grima, Maria Angela, et al.
Publicado: (2016)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

PB2273: EFFICACY OF OBINUTUZUMAB - BASED REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL SINGLE-CENTER STUDY
por: Ridova, Nevenka, et al.
Publicado: (2023)

Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma
por: Lien, I-Chia, et al.
Publicado: (2014)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

Cost-effectiveness analysis of treating transplant-eligible multiple myeloma patients in Macedonia
por: Qerimi, Vjollca, et al.
Publicado: (2018)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Thalidomide—Then and Now: Case Report of a Woman With Thalidomide Embryopathy and Review of Current Thalidomide Uses
por: Malik, Sara, et al.
Publicado: (2021)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Reproductive Issues in Long-Term Surviving Patients following Therapy for Hodgkin’s Disease in the Republic of North Macedonia: Risks of Infertility According to First-Line Treatment Regimens
por: Amzai, Gazmend, et al.
Publicado: (2022)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3
por: Qian, Shenxian, et al.
Publicado: (2005)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
por: Hjorth, Martin, et al.
Publicado: (2012)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Rethinking thalidomide.
Publicado: (1995)

Thalidomide and neurotrophism
por: Soper, Judith R., et al.
Publicado: (2018)

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals
por: Lachmann, P.J.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bc7gvnhob8ivla35tlukvs2sog